Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-07-01
1997-06-17
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514395, 514510, 514559, 514560, 514569, 514577, A61K 3141, A61K 31415
Patent
active
056397739
ABSTRACT:
This invention relates to an ocular hypotensive agent which comprises a compound represented by the formula: ##STR1## wherein R.sup.1 represents hydrogen or an optionally substituted hydrocarbon residue that may be bound via a hetero atom; R.sup.2 represents hydrogen or a hydrocarbon residue that may have a substituent; R.sup.3 represents a group capable of forming an anion or a group capable of changing thereto; X is a covalent bond between the 2 benzene rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n represents 1 or 2; ring A is a benzene ring having 1 or 2 optional substituents in addition to the group represented by COOR.sup.2, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 5102903 (1992-04-01), Smith
patent: 5128356 (1992-07-01), Naka et al.
patent: 5162326 (1992-11-01), Naka et al.
patent: 5183899 (1993-02-01), Naka et al.
patent: 5250554 (1993-10-01), Naka et al.
patent: 5284661 (1994-02-01), Morimoto et al.
FASB J.S., A1218 (1991), S. Wilson et al., "The Ocular Hypotensive Effect of DUP 753, a Non-Peptide Agiotensin II Antagonist", p. 4918.
Curr. Eye Res., 8, 841-849 (1989), Mallorga et al., "Angiotensin II Receptors Labelled with .sup.125 I-[Sar.sup.1, Ile.sup.8 ] All in Abino Rabbit Ocular Tissues", pp. 841-849.
J. Ocular Pharmacol., 3, 295-307 (1988), Watkins et al.
Am. J. Ophthalmol., 105, 674-677 (1988), Constad et al.
Constad et al., "Use of an AngiotensinConverting Enzyme Inhibitor in Ocular Hypertension and Primary Open-Angle Glaucoma", American Journal of Ophthalmology, vol. 105:674-677, (1988).
Journal of Pharmacol. Exp. Ther., vol. 266(3), Kawamura et al., "TCV 116, a Novel Angiotensin II Receptor Antagonist . . . Carotid Injury in Rats", 1993, abstract.
Deguchi Takaaki
Kubo Keiji
Ogawa Takahiro
Ivy C. Warren
Senju Pharmaceutical Co. Ltd.
Takeda Chemical Industries Ltd.
Williams Rosalynd
LandOfFree
Ocular hypotensive agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular hypotensive agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular hypotensive agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2158125